Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
Yongping Yang, Wei Shi, Olubukola M. Abiona, et al.
Vaccines (2021) Vol. 9, Iss. 2, pp. 73-73
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
Hasnat Tariq, Sannia Batool, Saaim Asif, et al.
Frontiers in Microbiology (2022) Vol. 12
Open Access | Times Cited: 144
Current and future nanoparticle vaccines for COVID-19
Mai N. Vu, Hannah G. Kelly, Stephen J. Kent, et al.
EBioMedicine (2021) Vol. 74, pp. 103699-103699
Open Access | Times Cited: 80
Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences
Elizabeth A. Clemmons, Kendra J. Alfson, John Dutton
Animals (2021) Vol. 11, Iss. 7, pp. 2039-2039
Open Access | Times Cited: 58
Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2
Chulwoo Kim, Jae-Deog Kim, Sang‐Uk Seo
The Journal of Microbiology (2022) Vol. 60, Iss. 3, pp. 335-346
Open Access | Times Cited: 28
Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
Kun Xu, Lianpan Dai, George F. Gao
International Immunology (2021) Vol. 33, Iss. 10, pp. 529-540
Open Access | Times Cited: 39
Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines
Dongliang Wang, Youqing Yuan, Bin Liu, et al.
International Journal of Biological Macromolecules (2023) Vol. 236, pp. 123979-123979
Open Access | Times Cited: 14
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Wasim A. Prates-Syed, Lorena C. S. Chaves, Karin P. Crema, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1409-1409
Open Access | Times Cited: 31
Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization
Alexandru A. Hennrich, Bevan Sawatsky, Rosalía Santos-Mandujano, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 4, pp. e1009064-e1009064
Open Access | Times Cited: 27
Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?
Ki‐Back Chu, Fu‐Shi Quan
Viruses (2023) Vol. 15, Iss. 2, pp. 392-392
Open Access | Times Cited: 11
Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
Ki-Back Chu, Hae-Ji Kang, Keon-Woong Yoon, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 920-920
Open Access | Times Cited: 22
Development of virus‐like particles‐based vaccines against coronaviruses
Chean Yeah Yong, Winnie-Pui-Pui Liew, Hui Kian Ong, et al.
Biotechnology Progress (2022) Vol. 38, Iss. 6
Open Access | Times Cited: 15
Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic
Wan Lu, Zhuangzhuang Zhao, Yao‐Wei Huang, et al.
International Journal of Biological Macromolecules (2022) Vol. 200, pp. 487-497
Open Access | Times Cited: 14
Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
Rik L. de Swart, George A. Belov
Current Opinion in Virology (2023) Vol. 62, pp. 101348-101348
Closed Access | Times Cited: 7
Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Manish Sharma
Health Sciences Review (2023) Vol. 9, pp. 100127-100127
Open Access | Times Cited: 6
The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate
Bo‐Kyoung Jung, Yong An, Jinju Jang, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263684-e0263684
Open Access | Times Cited: 10
Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody
Yi-Hsuan Chang, Min‐Feng Hsu, Wei-Nan Chen, et al.
JCI Insight (2024) Vol. 9, Iss. 10
Open Access | Times Cited: 1
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview
Ruth Henríquez, Isabel Muñoz‐Barroso
Heliyon (2024) Vol. 10, Iss. 15, pp. e34927-e34927
Open Access | Times Cited: 1
Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity
Tetsuya Nosaka, Junpei Ohtsuka, Tomomi Ohtsuka, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 6
Open Access | Times Cited: 1
Strengths and limitations of SARS-CoV-2 virus-like particle systems
Rokaia Sultana, Robert V. Stahelin
Virology (2024) Vol. 601, pp. 110285-110285
Open Access | Times Cited: 1
Self-assembling of coiled-coil peptides into virus-like particles: Basic principles, properties, design, and applications with special focus on vaccine design and delivery
Kisalay Jha, Puja Jaishwal, Thakur Prasad Yadav, et al.
Biophysical Chemistry (2024) Vol. 318, pp. 107375-107375
Closed Access | Times Cited: 1
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Manoj Kumar Sarangi, Sasmita Padhi, Gautam Rath, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 12, pp. 1739-1761
Closed Access | Times Cited: 7
Process development for cross‐flow diafiltration‐based VLP disassembly: A novel high‐throughput screening approach
Nils Hillebrandt, Philipp Vormittag, Annabelle Dietrich, et al.
Biotechnology and Bioengineering (2021) Vol. 118, Iss. 10, pp. 3926-3940
Open Access | Times Cited: 10
An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines
Doddy Irawan Setyo Utomo, Hamizah Suhaimi, Nor Azila Muhammad Azami, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1506-1506
Open Access | Times Cited: 3
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters
Rik L. de Swart, Olav S. de Leeuw, Nadia Oreshkova, et al.
Vaccine (2022) Vol. 40, Iss. 33, pp. 4676-4681
Open Access | Times Cited: 5
Self-Assembled Proteinaceous Nanoparticles for Co-Delivery of Antigens and Cytosine Phosphoguanine (CpG) Adjuvants: Implications for Nanovaccines
Xiang Li, Chao Pan, Caixia Li, et al.
ACS Applied Nano Materials (2023) Vol. 6, Iss. 9, pp. 7637-7648
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top